Abcur AB is a pharmaceutical company based in Helsingborg that specializes in the development and marketing of specialty medicines, particularly for hospital use and rare diseases. The company has established partnerships, notably with Alvotech, to produce biosimilar products. Abcur has received marketing approval for Gobivaz®, a biosimilar to Simponi®, and has acquired global rights to Zavesca®, a specialty brand aimed at treating rare diseases.
The company has also achieved acceptance from the European Medicines Agency for AVT23, a proposed biosimilar to Xolair®, and holds marketing authorizations for several other biosimilars. Abcur AB is focused on delivering innovative therapies that address complex health challenges and is committed to improving patient access to essential medications. Its operations are primarily concentrated within the European Economic Area, where it collaborates with regulatory bodies to facilitate product approvals.